Which patients should receive aspirin for primary prevention of cardiovascular disease? An economic evaluation

International Journal of Clinical Practice

Volumn 60, Issue 9, 2006, Pages 1129-1137

  Annemans, L ^a,b   Lamotte, M ^b   Kubin, M ^c   Evers, T ^c   Verheugt, F W A ^d  

^a GHENT UNIVERSITY   (Belgium)

^b IQVIA   (United States)

^c BAYER PHARMA AG   (Germany)

^d RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Aspirin; Cardiovascular disease; Cost effectiveness; Gastrointestinal bleeding; Primary prevention

Indexed keywords

ACETYLSALICYLIC ACID; PLACEBO;

ADULT; ARTICLE; BRAIN HEMORRHAGE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; CLINICAL STUDY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST CONTROL; COST EFFECTIVENESS ANALYSIS; DATA ANALYSIS; DRUG FATALITY; ECONOMIC EVALUATION; EUROPEAN UNION; FEMALE; GASTROINTESTINAL HEMORRHAGE; GERMANY; HEALTH CARE COST; HEALTH INSURANCE; HUMAN; ISCHEMIC HEART DISEASE; ITALY; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; META ANALYSIS; MONTE CARLO METHOD; PRIMARY PREVENTION; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; QUANTITATIVE ANALYSIS; SPAIN; SYSTEMATIC REVIEW; UNITED KINGDOM;

ASPIRIN; CARDIOVASCULAR DISEASES; COST-BENEFIT ANALYSIS; FEMALE; HUMANS; MALE; MIDDLE AGED; MODELS, ECONOMIC; PATIENT SELECTION; PLATELET AGGREGATION INHIBITORS; PRIMARY PREVENTION; QUALITY-ADJUSTED LIFE YEARS; RISK FACTORS;

EID: 33747180805     PISSN: 13685031     EISSN: 17421241     Source Type: Journal    
DOI: 10.1111/j.1742-1241.2006.01089.x     Document Type: Article

References (25)

1. Hayden M, Pignone M, Phillips C, Mulrow C. Aspirin for the primary prevention of cardiovascular events: A summary of the evidence for the US Preventive Services Task Force. Ann Intern Med 2002; 136: 161-72.
2. Eidelman RS, Herbert PR, Weisman SM, Hennekens CH. An update on aspirin in the primary prevention of cardiovascular disease. Arch Intern Med 2003; 163: 2006-10.
3. Peto R, Gray R, Collins R et al. Randomised trial of prophylactic daily aspirin in British male doctors. Br Med J 1988; 296: 313-6.
4. Steering Committee of the Physicians' Health Study Research Group. Final report on the aspirin component of the ongoing Physicians' Health Study. N Engl J Med 1989; 321: 129-35.
5. The Medical Research Council's General Practice Research Framework. Thrombosis prevention trial: Randomised trial of low-intensity oral anticoagulation with warfarin and low-dose aspirin in the primary prevention of ischaemic heart disease in men at increased risk. Lancet 1998; 351: 233-41.
6. Hansson L, Zanchetti A, Carruthers SG et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: Principal results of the Hypertension Optima Treatment (HOT) randomised trial. Lancet 1998; 351: 1755-62.
7. Collaborative Group of the Primary Prevention Project. Low-dose aspirin and vitamin E in people at cardiovascular risk: A randomised trial in general practice. Lancet 2001; 357: 89-95.
8. Ridker PM, Cook NR, Lee IM et al. A randomized trial of low-dose aspirin in the primary prevention of cardiovascular disease in women. N Engl J Med 2005; 352: 1293-304.
9. US Preventive Services Task Force. Aspirin for the primary prevention of cardiovascular events: Recommendations and rationale. Ann Intern Med 2002; 136: 157-60.
10. Pearson TA, Blair SN, Daniels SR et al. AHA guidelines for primary prevention of cardiovascular disease and stroke: 2002 Update. Consensus panel guide to comprehensive risk reduction for adult patients without coronary or other atherosclerotic vascular diseases: American Heart Association Science Advisory and Coordinating Committee. Circulation 2002; 106: 388-91.
11. Anderson KM, Odell PM, Wilson PW, Kannel WB. Cardiovascular disease risk profiles. Am Heart J 1991; 121: 293-8.
12. De Backer G, Ambrosioni E, Borch-Johnsen K et al. European guidelines on cardiovascular disease prevention in clinical practice: Third Joint Task Force of European and Other Societies on Cardiovascular Disease Prevention in Clinical Practice. Eur Heart J 2003; 24: 1601-10.
13. Conroy RM, Pyorala K, Fitzgerald AP et al. Estimation of ten-year risk of fatal cardiovascular disease in Europe: The SCORE project. Eur Heart J 2003; 24: 987-1003.
14. Lamotte M, Annemans L, Evers T, Kubin M. A multi-country economic evaluation of low-dose aspirin in the primary prevention of cardiovascular disease. Pharmacoeconomics 2006; 24: 155-69.
15. Wood D, De Backer G, Faergeman O et al. Prevention of coronary heart disease in clinical practice: Recommendations of the Second Joint Task Force of European and other Societies on Coronary Prevention. Atherosclerosis 1998; 140: 199-270.
16. Collinson J, Flather MD, Fox KA et al. Clinical outcomes, risk stratification and practice patterns of unstable angina and myocardial infarction without ST-elevation: Prospective registry of acute ischaemic syndromes in the UK (PRAIS-UK). Eur Heart J 2000; 21: 1450-57.
17. Euroaspire II Study Group. Lifestyle and risk factor management and use of drug therapies in coronary patients from 15 countries. Principal results from Euroaspire II Euro Heart Survey Programme. Eur Heart J 2001; 22: 554-72.
18. CAPRIE Steering Committee. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet 1996; 348: 1329-39.
19. World Health Organisation. Life Tables and Methods. Available at: http://www3.who.int/whosis/menu.cfm?path=whosis,life. Accessed 11 May 2006.
20. Tsevat J, Goldman L, Soukup JR et al. Stability of time-trade off utilities in survivors of myocardial infarction. Med Decis Making 1993; 13: 161-5.
21. Tengs TO, Lin TH. A meta-analysis of quality of life estimates for stroke. Pharmacoeconomics 2003; 21: 191-200.
22. Kuntz KM, Tsevat J, Goldman L, Weinstein MC. Cost-effectiveness of routine coronary angiography after acute myocardial infarction. Circulation 1996; 94: 957-65.
23. Catherwood E, Fitzpatrick WD, Greenberg ML, Holzberger PT, Malenka DJ, Gerling BR, et al. Cost-effectiveness of cardioversion and antiarrhythmic therapy in nonvalvular atrial fibrillation. Ann Intern Med 1999; 130: 625-36.
24. Antithrombotic Trialists' Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. Br Med J 2002; 324: 71-86.
25. Pignone M, Earnshaw S, Tice JA, Pletcher MJ. Aspirin, statins, or both drugs for the primary prevention of coronary heart disease events in men: A cost-utility analysis. Ann Intern Med 2006; 144: 326-36.